JP2021523213A5 - - Google Patents
Info
- Publication number
- JP2021523213A5 JP2021523213A5 JP2020564674A JP2020564674A JP2021523213A5 JP 2021523213 A5 JP2021523213 A5 JP 2021523213A5 JP 2020564674 A JP2020564674 A JP 2020564674A JP 2020564674 A JP2020564674 A JP 2020564674A JP 2021523213 A5 JP2021523213 A5 JP 2021523213A5
- Authority
- JP
- Japan
- Prior art keywords
- icos
- cells
- seq
- agonist
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862671181P | 2018-05-14 | 2018-05-14 | |
| US62/671,181 | 2018-05-14 | ||
| US201862679346P | 2018-06-01 | 2018-06-01 | |
| US62/679,346 | 2018-06-01 | ||
| US201862750026P | 2018-10-24 | 2018-10-24 | |
| US62/750,026 | 2018-10-24 | ||
| US201962827312P | 2019-04-01 | 2019-04-01 | |
| US62/827,312 | 2019-04-01 | ||
| PCT/US2019/032184 WO2019222188A1 (en) | 2018-05-14 | 2019-05-14 | Methods of treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021523213A JP2021523213A (ja) | 2021-09-02 |
| JP2021523213A5 true JP2021523213A5 (enExample) | 2022-05-20 |
Family
ID=66690990
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020564674A Pending JP2021523213A (ja) | 2018-05-14 | 2019-05-14 | 癌を治療する方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US11292840B2 (enExample) |
| EP (1) | EP3793598A1 (enExample) |
| JP (1) | JP2021523213A (enExample) |
| CN (1) | CN112703012A (enExample) |
| WO (1) | WO2019222188A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013059740A1 (en) | 2011-10-21 | 2013-04-25 | Foundation Medicine, Inc. | Novel alk and ntrk1 fusion molecules and uses thereof |
| EP4223770A3 (en) | 2012-11-05 | 2023-10-18 | Foundation Medicine, Inc. | Novel fusion molecules and uses thereof |
| CA2898326C (en) | 2013-01-18 | 2022-05-17 | Foundation Medicine, Inc. | Methods of treating cholangiocarcinoma |
| US20200024351A1 (en) * | 2017-04-03 | 2020-01-23 | Jounce Therapeutics, Inc. | Compositions and Methods for the Treatment of Cancer |
| US20210380942A1 (en) * | 2018-10-24 | 2021-12-09 | Jounce Therapeutics, Inc. | Methods and compositions for the treatment of cancer and infectious diseases |
| WO2020243021A2 (en) | 2019-05-24 | 2020-12-03 | Foundation Medicine, Inc. | Ntrk fusion molecules and uses thereof |
| US20220396839A1 (en) | 2019-11-12 | 2022-12-15 | Foundation Medicine, Inc. | Methods of detecting a fusion gene encoding a neoantigen |
| WO2021146303A1 (en) * | 2020-01-13 | 2021-07-22 | Jounce Therapeutics, Inc. | Methods for the treatment of cancer |
| EP4114979A4 (en) | 2020-03-04 | 2025-08-27 | Found Medicine Inc | BCOR REDESIGNS AND THEIR USES |
| JP2023521825A (ja) * | 2020-04-20 | 2023-05-25 | ジョンス セラピューティクス， インコーポレイテッド | ワクチン接種及び感染性疾患の治療のための組成物及び方法 |
| GB202007099D0 (en) | 2020-05-14 | 2020-07-01 | Kymab Ltd | Tumour biomarkers for immunotherapy |
| CN112807425A (zh) * | 2021-01-14 | 2021-05-18 | 南方医科大学深圳医院 | 一种tTIM融合蛋白疫苗、制备方法及应用 |
| CA3219336A1 (en) | 2021-05-18 | 2022-11-24 | Kymab Limited | Uses of anti-icos antibodies |
| US20250084482A1 (en) | 2021-06-25 | 2025-03-13 | Foundation Medicine, Inc. | Methods of using somatic hla-i loh to predict response of immune checkpoint inhibitor-treated patients with lung cancer |
| EP4525991A1 (en) | 2022-05-18 | 2025-03-26 | Kymab Limited | Uses of anti-icos antibodies |
| JP2025160816A (ja) * | 2024-04-10 | 2025-10-23 | イミューンオンコ バイオファーマシューティカルズ （シャンハイ） インコーポレイテッド | 古典的ホジキンリンパ腫に対する併用療法 |
| CN118516308B (zh) * | 2024-07-22 | 2024-10-22 | 深圳市中佳生物医疗科技有限公司 | 免疫调节剂在制备增强nk细胞毒性作用的产品中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| KR102023661B1 (ko) | 2011-03-31 | 2019-09-23 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | Icos에 대한 항체 및 이의 용도 |
| CA2889182A1 (en) | 2012-10-26 | 2014-05-01 | The University Of Chicago | Synergistic combination of immunologic inhibitors for the treatment of cancer |
| BR112015022462A8 (pt) | 2013-03-15 | 2019-11-26 | Bristol Myers Squibb Co | inibidores de ido, composição farmacêutica, método de inibição de atividade de indolamina 2,3-dioxigenase e uso dos referidos inibidores |
| MA53297A (fr) | 2015-03-23 | 2022-05-04 | Jounce Therapeutics Inc | Anticorps anti-icos |
| US10968277B2 (en) * | 2015-10-22 | 2021-04-06 | Jounce Therapeutics, Inc. | Gene signatures for determining ICOS expression |
| WO2018029474A2 (en) | 2016-08-09 | 2018-02-15 | Kymab Limited | Anti-icos antibodies |
| RU2764548C2 (ru) * | 2016-08-09 | 2022-01-18 | Кимаб Лимитед | Анти-icos антитела |
-
2019
- 2019-05-14 EP EP19728206.4A patent/EP3793598A1/en not_active Withdrawn
- 2019-05-14 WO PCT/US2019/032184 patent/WO2019222188A1/en not_active Ceased
- 2019-05-14 CN CN201980047070.3A patent/CN112703012A/zh active Pending
- 2019-05-14 JP JP2020564674A patent/JP2021523213A/ja active Pending
- 2019-05-14 US US16/411,744 patent/US11292840B2/en not_active Expired - Fee Related
-
2022
- 2022-03-31 US US17/709,712 patent/US20220332823A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ishikawa et al. | Phase I clinical trial of adoptive transfer of expanded natural killer cells in combination with I g G 1 antibody in patients with gastric or colorectal cancer | |
| Makita et al. | Clinical development of anti‐CD 19 chimeric antigen receptor T‐cell therapy for B‐cell non‐Hodgkin lymphoma | |
| JP5665702B2 (ja) | Ｎｋ細胞増強化合物を使用する治療抗体の有効性を増大させる方法および組成物 | |
| Goldwater et al. | A phase 1, randomized ascending single‐dose study of antagonist anti‐human CD40 ASKP1240 in healthy subjects | |
| KR20190123749A (ko) | 항-tigit 항체 | |
| JP2018537962A5 (enExample) | ||
| KR20150042784A (ko) | Ｃａｒ의 항-종양 활성에 대한 독성 관리 | |
| Dokouhaki et al. | Adoptive immunotherapy of cancer using ex vivo expanded human γδ T cells: A new approach | |
| RU2012134369A (ru) | Биомаркеры иммуномодулирующих эффектов у людей, подвергнутых лечению антиметаллами против cd200 | |
| CN112703012A (zh) | 治疗癌症的方法 | |
| CN109385403A (zh) | 靶向gpc3的car nk细胞 | |
| NO159884B (no) | Monoklonalt antistoff. | |
| Magalhaes et al. | CD19 chimeric antigen receptor T cells from patients with chronic lymphocytic leukemia display an elevated IFN-γ production profile | |
| WO2017205213A1 (en) | Combination therapy of abemaciclib and immune checkpoint modulators for use in the treatment of cancer | |
| JP2020510444A (ja) | 抗がん剤の臨床成果を予測する方法 | |
| Luo et al. | Natural Killer Cell‐Mediated Antitumor Immunity: Molecular Mechanisms and Clinical Applications | |
| Ma et al. | Automatic generation of lymphocyte heterogeneity: Division‐dependent changes in the expression of CD27, CCR7 and CD45 by activated human naive CD4+ T cells are independently regulated | |
| Nelson et al. | TT hybridoma product specifically suppresses tumor immunity. | |
| US20240207311A1 (en) | Tumor infiltrating lymphocytes therapy | |
| WO2021096753A1 (en) | Cd200 receptor antagonist binding molecules | |
| Batatinha et al. | Exercise-mobilized lymphocytes enhance the function of cytokine-induced memory-like NK cells against myeloid leukemia | |
| Zhang et al. | Enhancement of B7-H3 chimeric antigen receptor-T cell efficacy via the coexistence effect of IL-7, IL-15 and CCL19 for pancreatic and lung xenograft tumors | |
| CN115724979B (zh) | 一种多功能重组抗体及其制备方法和应用 | |
| WO2020086802A1 (en) | Methods and compositions for the treatment of cancer and infectious diseases | |
| CN120904358B (zh) | 一种新型il-15融合蛋白及其应用 |